From: The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Cancer type | Host country | |||
---|---|---|---|---|
China | United States | Rest of world | Total | |
Non-small-cell lung cancer | 39 | 26 | 35 | 100 |
Breast cancer | 10 | 30 | 30 | 70 |
Esophageal cancer | 46 | 8 | 6 | 60 |
Melanoma | 10 | 41 | 9 | 60 |
Urothelial carcinoma | 10 | 29 | 20 | 59 |
Head and neck squamous cell carcinoma | 13 | 29 | 14 | 56 |
Colorectal cancer | 16 | 13 | 16 | 45 |
Gastric cancer | 25 | 11 | 8 | 44 |
Hepatocellular carcinoma | 23 | 7 | 6 | 36 |
Renal cancer | 5 | 10 | 4 | 19 |
Pancreatic cancer | 1 | 14 | 4 | 19 |
Glioma | 3 | 10 | 2 | 15 |
Soft tissue sarcoma | 4 | 6 | 2 | 12 |
Cutaneous squamous cell carcinoma | 1 | 8 | 2 | 11 |
Mesothelioma | 0 | 11 | 0 | 11 |
Ovarian cancer | 0 | 5 | 5 | 10 |
Solid tumor | 0 | 6 | 1 | 7 |
Biliary tract cancer | 4 | 1 | 1 | 6 |
Prostate cancer | 0 | 5 | 1 | 6 |
Cervical cancer | 2 | 2 | 0 | 4 |
Endometrial carcinoma | 0 | 4 | 0 | 4 |
Merkel cell carcinoma | 0 | 3 | 1 | 4 |
Thyroid cancer | 2 | 1 | 0 | 3 |
Small-cell lung cancer | 2 | 0 | 0 | 2 |
Pancreatic cancer and colorectal cancer | 0 | 1 | 0 | 1 |
Gastric cancer and colorectal cancer | 0 | 0 | 1 | 1 |
NSCLC and HCC | 0 | 1 | 0 | 1 |
NSCLC and Gastric cancer | 0 | 0 | 1 | 1 |
Colorectal cancer and pancreatic cancer | 0 | 1 | 0 | 1 |
Total | 216 | 283 | 169 | 668 |